Tumour brain: Pretreatment cognitive and affective disorders caused by peripheral cancers

Mampay, Myrthe; Flint, Melanie S.; Sheridan, Graham K.

doi:10.1111/bph.15571

Cited by 18 publications

(13 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data demonstrate that patients with breast cancer recruited in routine clinical practice report increased functional strain especially in the domains of EF and CF, prior to the start of their treatment compared to patients with primarily benign entities. Other trials reported that cancer itself might cause affective and cognitive impairment even before treatment initiation [38]. Additionally, pretreatment worry has been shown to be associated with a decline in cognitive functioning [39].…”

Section: Main Findingsmentioning

confidence: 99%

Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients

Karsten

Roehle

Albers

et al. 2022

European Journal of Cancer

View full text Add to dashboard Cite

To deliver patient-reported outcome (PRO) reference data for breast cancer and various other breast diseases to facilitate the interpretation of PRO scores during routine breast cancer treatment. Methods: To determine reference baseline values for the PRO measures EORTC QLQ-C30 and EORTC QLQ-BR23, PRO data captured in the breast cancer centre at Charite ´e Universita ¨tsmedizin Berlin from 2016 to 2021 were evaluated. As part of the clinical routine, ambulatory patients were asked to answer a digital survey regarding their medical history, current health status and health-related quality of life using the aforementioned questionnaires prior to their doctor's appointment in the outpatient breast clinic. Adjusted linear and variable dispersion beta regression models were used to compare different diagnosis groups. Results: A total of 3689 patients were included in the digital PRO program, of which 1478 were eligible for this study; 729 had invasive breast cancer or ductal carcinoma in situ, 270 patients were diagnosed with fibroadenoma and 479 patients had other breast diseases such as cysts, mastopathy or abscesses. Overall, patients with breast cancer reported worse scores in almost all domains except for role functioning, sexual functioning and body image.

show abstract

Section: Main Findingsmentioning

confidence: 99%

Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients

Karsten

Roehle

Albers

et al. 2022

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Tumors may disrupt the brain clock, leading to non-circadian HPA-axis activation and disrupted cortisol release [ 112 ]. A potential mechanism by which cancers may affect the brain clocks is by secreting cytokines that lead to neuroinflammation, blood–brain barrier breakdown, and thereby circadian rhythm disruption and sleep disruption [ 113 ]. Initially, cortisol levels may be elevated after one or a few nights of poor sleep, leading to immune-suppression and increased risk of infection.…”

Section: What Are the Important Mechanisms Underlying The Pathologica...mentioning

confidence: 99%

A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients

Jensen

Oliva

Andersson

et al. 2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

Sleep is a basic need that is frequently set aside in modern societies. This leads to profound but complex physiological maladaptations in the body commonly referred to as circadian disruption, which recently has been characterized as a carcinogenic factor and reason for poor treatment outcomes, shortened survival, and reduced quality of life in cancer patients. As sleep and circadian physiology in cancer patients spans several disciplines including nursing science, neurology, oncology, molecular biology and medical technology, there is a lack of comprehensive and integrated approaches to deal with this serious and growing issue and at best a fractionated understanding of only part of the problem among researchers within each of these segments. Here, we take a multidisciplinary approach to comprehensively review the diagnosis and impact of sleep and circadian disruption in cancer patients. We discuss recent discoveries on molecular regulation of the circadian clock in healthy and malignant cells, the neurological and endocrine pathways controlling sleep and circadian rhythmicity, and their inputs to and outputs from the organism. The benefits and drawbacks of the various technologies, devices, and instruments used to assess sleep and circadian function, as well as the known consequences of sleep disruption and how sleep can be corrected in cancer patients, will be analyzed. We will throughout the review highlight the extensive crosstalk between sleep, circadian rhythms, and metabolic pathways involved in malignancy and identify current knowledge gaps and barriers for addressing the issue of sleep and circadian disruption in cancer patients. By addressing these issues, we hope to provide a foundation for further research as well as better and more effective care for the patients in the future.

show abstract

“…Different studies have established a relation between alterations in circadian rhythm genes and cancer [32,34]. Specifically, one of the genes associated with different types of cancer is cry [35][36][37]. Thus, this study aims to investigate the role of cry in a Drosophila GB model.…”

Section: Discussionmentioning

confidence: 99%

Circadian Gene cry Controls Tumorigenesis through Modulation of Myc Accumulation in Glioblastoma Cells

Jarabo¹,

Pablo²,

González-Blanco³

et al. 2022

IJMS

View full text Add to dashboard Cite

Glioblastoma (GB) is the most frequent malignant brain tumor among adults and currently there is no effective treatment. This aggressive tumor grows fast and spreads through the brain causing death in 15 months. GB cells display a high mutation rate and generate a heterogeneous population of tumoral cells that are genetically distinct. Thus, the contribution of genes and signaling pathways relevant for GB progression is of great relevance. We used a Drosophila model of GB that reproduces the features of human GB and describe the upregulation of the circadian gene cry in GB patients and in a Drosophila GB model. We studied the contribution of cry to the expansion of GB cells and the neurodegeneration and premature death caused by GB, and we determined that cry is required for GB progression. Moreover, we determined that the PI3K pathway regulates cry expression in GB cells, and in turn, cry is necessary and sufficient to promote Myc accumulation in GB. These results contribute to understanding the mechanisms underlying GB malignancy and lethality, and describe a novel role of Cry in GB cells.

show abstract

Tumour brain: Pretreatment cognitive and affective disorders caused by peripheral cancers

Cited by 18 publications

References 158 publications

Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients

Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients

A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients

Circadian Gene cry Controls Tumorigenesis through Modulation of Myc Accumulation in Glioblastoma Cells

Contact Info

Product

Resources

About